SALT LAKE CITY, APRIL 20, 2020 – In what could be an absolute game-changer in the global quest to treat and prevent COVID-19, Utah-based Xlear in partnership with Utah State University Institute of Antiviral Research and Dr. Gustavo Ferrer are proud to announce today that they have completed successful initial in vitro testing using a new nasal spray. While further research is needed for nasal administration, the ingredients in this spray have been used safely for decades when taken orally.
The concept is a very simple concept…if 90% of the viral load is in the upper airway wouldn’t you think the best place to put an antiviral would be in a nasal spray? This study is the first step to showing that this concept could work…quickly.
Dr. Ferrer and Nate Jones, Xlear CEO are both available for comment.
About Xlear
Xlear Inc. is a pharmaceutical products company based in American Fork, Utah. Xlear for more than twenty years has been a leading manufacturer and distributor of Xylitol-based nasal and oral care products that can be found in more than 30,000 stores nationwide to include CVS, Target, Whole Foods, Kroger, Sprouts and RITE Aid.
Media Contact:
Jeff Gulko
THE GULKO GROUP
617.304.7339
jeff@thegulkogroup.com
www.thegulkogroup.com
Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…
PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the…
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating…